Michael P. Hill

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study

Katarzyna Sieradzan, Susan H. Fox, Michael P. Hill et al. · Neurology · 2001 · 347 citations

Medicine, Pharmacology, Pharmacotherapy +17

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease

Vincenzo Di Marzo, Michael P. Hill, Tiziana Bisogno et al. · The FASEB Journal · 2000 · 305 citations

Life Sciences, Neuroscience, Pharmacology +14

A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease

Mario van der Stelt, Susan H. Fox, Michael P. Hill et al. · The FASEB Journal · 2005 · 201 citations

Life Sciences, Neuroscience, Pharmacology +17

Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

Susan H. Fox, Brian Henry, Michael P. Hill et al. · Movement Disorders · 2002 · 164 citations

Life Sciences, Neuroscience, Pharmacology +17

Fipamezole (JP‐1730) is a potent α₂ adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease

Juha‐Matti Savola, Michael P. Hill, Mia Engström et al. · Movement Disorders · 2003 · 156 citations

Medicine, Neuroscience, Pharmacology +17